Modulating IDO1 and TDO Inhibition Through Structural Modification of Diaryl Hydroxylamines.

Area of Science:

• Medicinal Chemistry
• Enzyme Inhibition
• Cancer Immunology

Background:

• Indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO) are key enzymes in tryptophan metabolism that promote tumor immune escape.
• Diaryl hydroxylamines are emerging scaffolds with potential dual inhibitory activity against IDO1 and TDO.

Purpose of the Study:

• To design and synthesize novel diaryl hydroxylamine analogs to probe structure-activity relationships (SAR) for IDO1 and TDO inhibition.
• To identify key structural determinants for potent and selective inhibition of these dioxygenases.

Main Methods:

• Synthesis of a diverse series of diaryl hydroxylamines and related analogs with systematic structural modifications.
• In vitro enzyme inhibition assays to determine IC50 values against IDO1 and TDO.

Main Results:

• 1,1'-Diaryl hydroxylamines with five-membered heterocycles and electron-deficient aryl groups demonstrated micromolar to submicromolar inhibition of both IDO1 and TDO.
• Scaffold elongation led to increased IDO1 preference, while thiol or oxime bioisosteres showed reduced potency.
• Compounds 28l (O-benzylhydroxylamine) and 16j (1,1'-diaryl hydroxylamine) exhibited potent dual IDO1/TDO inhibition (IC50s 0.031/2.9 μM and 0.18/5.5 μM, respectively).

Conclusions:

• The SAR study elucidated critical structural features governing IDO1 and TDO inhibition.
• Fluorinated diaryl hydroxylamines represent promising leads for developing dual IDO1/TDO inhibitors with potential applications in cancer immunotherapy.
• These findings also suggest potential for developing fluorinated hydroxylamines as PET imaging probes.